ASX healthcare shares are showing renewed momentum, with two of the sector’s biggest names staging notable rebounds in recent weeks. At the time of writing, both CSL Ltd (ASX: CSL) and ResMed Inc (ASX: RMD) are trading higher. 

CSL shares have been one of the standout movers in the sector. The stock is up around 7% over the past five trading days and 34% over the past month, reflecting a sharp improvement in sentiment after a brutal sell-off. Despite this recovery, CSL remains heavily out of favour on a longer horizon, still down 28% year to date and nearly 49% over the past 12 months.

ResMed has also begun to recover, although its rebound has been more gradual. The ASX healthcare share is up about 10% over the past five trading days and 13% over the past month. Even so, it remains down 14% year to date and roughly 21% over the past year, leaving it well below its recent highs.

Now, the key question for investors is whether this marks the start of a sustained recovery or just a short-term bounce.

CSL: sentiment improves, but challenges remain

Earnings downgrades, acquisition concerns and a broader reset in market expectations drove the sharp decline in CSL shares. This led to a significant de-rating as investors reassessed what was once considered one of the ASX’s most reliable compounders.

The underlying business remains strong. CSL maintains its position as one of the world’s largest plasma-derived therapies companies. However, the market is now focused on whether management can restore consistent earnings momentum. Particularly as supply constraints and pricing dynamics continue to weigh on performance in key markets.

Morgans continues to support the stock. It retains a buy rating on the $58 billion ASX healthcare share with a price target of $147.59. This points to a 19% upside at current price levels.

The broker notes that the long-term story remains intact. However, a sustained recovery in sentiment may take several quarters to fully materialise as investors wait for clearer evidence in the numbers.

ResMed: growth remains intact despite volatility

The price weakness of the $44 billion ASX healthcare share has been driven more by valuation compression than by any meaningful deterioration in business performance. Broader concerns around healthcare growth stocks have also weighed on sentiment, contributing to the stock’s decline over the past year.

Despite this, the company’s fundamentals remain solid. In Q3 FY26, ResMed reported revenue rising 11% to US$1.43 billion, while non-GAAP earnings per share were up 21% to US$2.86.

Even after its recent rebound, ResMed remains at its lowest valuation level in more than a decade. It’s trading on approximately 16 times forward earnings despite expectations for double-digit earnings per share growth.

Morgans has retained a buy rating with a price target of $41.72, implying around 36% upside from current levels. The broker highlights that the current valuation may underestimate the company’s long-term growth potential.

The post 2 ASX healthcare shares crashing, now bouncing: buy, hold or sell? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Dexus, Resmed, BHP shares
• Down 22%! 3 reasons to buy the big dip in ResMed shares today
• 3 ASX 200 shares to buy now: experts
• Why BHP and these ASX shares could be strong buys this week
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

For retirees looking to complement their superannuation with quality investments, there are several factors to consider. 

Dividend stocks are a fantastic option because they provide passive income that can supplement retirement savings while offering the potential for long-term capital growth. 

Companies with a strong history of paying consistent, and ideally increasing, dividends can provide a reliable income stream, although it’s important to remember that dividends are not guaranteed and share prices can fluctuate. 

Another important consideration is the impact of inflation.

Many retirees will need to live off superannuation for more than 20 or 30 years, and inflation can eat into the purchasing power of their savings over time. 

Investments that have the potential to deliver returns above the rate of inflation can help preserve wealth and maintain living standards throughout retirement. 

Building a diversified portfolio that includes growth assets alongside income-producing investments can provide a balance between protecting capital and ensuring retirement savings continue to work over the long term.

Here are five options to consider that stretch across growth and income assets to compliment your superannuation. 

Dividend stocks to consider 

For retirees looking to target dividend stocks, one great option is Telstra Group Ltd (ASX: TLS). 

It is often considered an attractive dividend stock for retirees because of its established market position, relatively stable cash flows, and history of paying consistent dividends. 

Its essential telecommunications services provide resilient earnings, making it a popular choice for investors seeking reliable income alongside the potential for modest long-term capital growth.

Another dividend stock with a strong reputation is BHP Group Ltd (ASX: BHP). 

It is a popular dividend stock for retirees because of its strong balance sheet, global leadership in mining, and history of returning a significant portion of profits to shareholders through dividends. 

While dividend payments can fluctuate with commodity prices, BHP’s exposure to essential resources such as iron ore and copper provides the potential for attractive income and long-term growth.

Finally, income investors might also target Macquarie Group Ltd (ASX: MQG). 

While its dividend may be more cyclical than those of traditional defensive companies, Macquarie’s exposure to infrastructure, asset management, and renewable energy provides both income potential and opportunities for long-term capital growth.

Growth shares to consider 

While passive income is important, it isn’t the entire story for a healthy compliment to your superannuation. 

For investors looking to outpace inflation during retirements, two great ASX ETFs to consider are: 

• BetaShares Nasdaq 100 ETF (ASX: NDQ)
• Vanguard Diversified High Growth Index ETF (ASX: VDHG)

These ASX ETFs focus on strong long-term growth potential. 

This makes them both an attractive option for retirees seeking capital appreciation to help offset the effects of inflation.

They also offer broad international diversification helps reduce single-market risk while providing long-term growth potential.

The post 5 of the best investments on the ASX right now to complement your superannuation appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Dexus, Resmed, BHP shares
• Are these some of the best Betashares ETFs to buy?
• Up 57%! 3 compelling reasons to still buy BHP shares today
• Buy, hold, sell: BHP, Woodside, PLS Group shares
• Buy, hold, sell: Pro Medicus, BHP, Woolworths shares

Motley Fool contributor Aaron Bell has positions in BHP Group and BetaShares Nasdaq 100 ETF. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended BetaShares Nasdaq 100 ETF and Macquarie Group. The Motley Fool Australia has positions in and has recommended BetaShares Nasdaq 100 ETF and Telstra Group. The Motley Fool Australia has recommended BHP Group and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Artificial intelligence has produced a long list of buzzy stock ideas. Most of them sit in the United States.

But the infrastructure AI actually runs on, the data centres, the power grids, the networks, is being built right here in Australia.

Three ASX AI stocks are capturing that opportunity in very different but equally compelling ways.

NextDC: where AI workloads live

NextDC Ltd (ASX: NXT) is Australia’s largest independent data centre operator, and the closest thing on the ASX to a direct, pure-play bet on AI infrastructure demand.

The numbers confirm the demand is real and accelerating.

Contracted utilisation surged 60% to 667MW in the March 2026 quarter alone. This was driven by massive contract wins as AI workloads requiring intensive computing power, storage, and connectivity flooded into NextDC’s facilities.

The company’s forward order book, combined with existing billing, is expected to generate contracted EBITDA in excess of A$1 billion. This is more than four times the midpoint of FY26 guidance, as that contracted capacity converts to revenue progressively from FY26 through FY30.

OpenAI, one of the world’s largest and best-funded AI companies, is the foundational customer for NextDC’s $7 billion AI data centre campus in Western Sydney. This relationship relationship validates both the strategic importance of Australian AI infrastructure and NextDC’s position within it.

The risks are equally visible.

$5 billion in FY27 capital expenditure means execution matters enormously given the large sums of capital invested.

Goodman Group: a surprise ASX AI infrastructure play

Goodman Group (ASX: GMG) is the landlord of the AI revolution.

Before a data centre can be built, someone needs to secure the land, obtain planning approvals, connect the power, and deliver the shell.

That is Goodman’s role, and it is an increasingly scarce and valuable one.

Data centres now make up 73% of Goodman’s development pipeline, which is on track to reach $18 billion by June 2026. The company possesses a global power bank of 6.4 gigawatts across 16 cities that took years to assemble and that no newcomer can replicate quickly.

This is Goodman’s competitive advantage.

Morgans has noted that industry data centre capital expenditure requirements likely exceed global capital market funding capacity. This statement describes a market where the constraint is not demand but the ability to build fast enough.

Consequently, Goodman is positioned on the supply side of that constraint, with secured power, sites, and locked-in capital partners already in place.

On the broker side, Morgans retains a buy rating on Goodman with a $36 price target, and UBS endorses Goodman’s outlook with a $36.41 price target.

Megaport: how AI workloads move

Megaport Ltd (ASX: MP1) has changed the most of the three over the past twelve months.

The company was already known as a network-as-a-service provider connecting businesses to cloud platforms.

But its acquisition of Latitude.sh pushed it deeper into the AI infrastructure stack by adding high-performance GPU, CPU, and storage capabilities alongside its core connectivity offering.

Subsequently, Megaport rose almost 50% in FY26, smashing the ASX 200’s 3% gain, as the market began to recognise it as an AI infrastructure contender rather than simply a cloud connectivity story.

$254 million in new AI contracts through Latitude.sh, generating $90.6 million in annualised recurring revenue, confirmed that AI demand is already flowing into the business.

CEO Michael Reid described the contract wins as evidence that

Megaport is becoming an essential platform for powering the applications of tomorrow.

The risks across all three ASX AI stocks

However, none of these three ASX AI stocks is without risk.

NextDC’s $5 billion FY27 capex plan means any slip in execution or AI demand would hit the stock hard.

Goodman’s premium valuation reflects how much the market has already priced into its data centre transition. This leaves little room for disappointment.

Megaport has to prove the Latitude.sh contracts convert into attractive returns over time, not just headline contract values.

Additionally, all three are also sensitive to interest rate movements given their capital-intensive operating models.

Foolish takeaway for ASX AI stocks

NextDC, Goodman, and Megaport each capture the AI infrastructure opportunity from a different angle.

NextDC provides the capacity. Goodman provides the land and power. Megaport provides the connectivity.

For investors who believe AI-driven infrastructure demand will keep accelerating, all three deserve a place on the watchlist.

The post The best AI stocks on the ASX right now appeared first on The Motley Fool Australia.

More reading

• ASX 200 tech shares tanked in FY26, but there were 3 winners
• Why did Megaport shares smash the ASX 200 in FY26?
• 10 of the best ASX shares to buy in FY 2027
• Should you buy property or stocks? Here’s what you need to consider
• Should I buy the rebound in CBA shares today?

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goodman Group and Megaport. The Motley Fool Australia has recommended Goodman Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.